Inactive Instrument

Coeptis Therapeutics, Inc. OTC Markets

COEP

US19207C1045

Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc..

October 23, 2019

Coeptis Pharmaceuticals, Inc. entered into a binding agreement to acquire Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc. (OTCPK:AMBS) on November 28, 2018. Coeptis will issue 7.5 million shares as part of consideration and an additional 7.5 million shares being delivered to Elto Pharma shareholders upon the completion of certain milestones.

Coeptis Pharmaceuticals, Inc. terminated the acquisition of Elto Pharma, Inc. from PsychoGenics Inc. and Amarantus BioScience Holdings, Inc. (OTCPK:AMBS) on October 24, 2019.

Latest news about Coeptis Therapeutics, Inc.

Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 26	CI
Coeptis Therapeutics Holdings, Inc. Adds Autoimmune Indications to Exclusive License Agreement with University of Pittsburgh for SNAP-CAR T and SNAP-CAR NK	Feb. 26	CI
Coeptis Therapeutics to Pursue Phase 2 Program Using Proprietary First-In-Class Allogeneic NK Cell Therapy for the Treatment of Viral Infections	Feb. 07	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Coeptis Therapeutics Holdings, Inc. announced that it has received $2 million in funding	Nov. 02	CI
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $2 million in funding	23-10-23	CI
Coeptis Therapeutics Expands License Agreement with University of Pittsburgh to Include SNAP-CAR NK Cell Technology	23-10-11	CI
Coeptis Therapeutics Holdings, Inc. announced that it expects to receive $0.5 million in funding	23-09-28	CI
Ladenburg Thalmann Starts Coeptis Therapeutics Holdings at Buy, $3 Price Target	23-09-22	MT
Certain Pre-Funded Warrants of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Options of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Warrants of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Certain Common Stock of Coeptis Therapeutics Holdings, Inc. are subject to a Lock-Up Agreement Ending on 13-SEP-2023.	23-09-12	CI
Coeptis Therapeutics Holdings, Inc. Appoints Colleen Delaney, MD, as Chief Scientific and Medical Officer	23-08-30	CI
Coeptis Therapeutics Holdings, Inc. Completes Exclusive License for Allogeneic Immuno-Oncology Platform and Clinical Stage Assets from Deverra Therapeutics	23-08-17	CI
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
Coeptis Therapeutics Holdings, Inc Files FDA 513(g) Submission for CD38 In Vitro Companion Diagnostic	23-08-01	CI
Coeptis Therapeutics Holdings Closes $3.5 Million Underwritten Offering	23-06-16	MT
Top Premarket Decliners	23-06-14	MT
EF Hutton Assumes COEP at Coeptis Therapeutics at Buy With $10 Price Target	23-05-25	MT
Coeptis Therapeutics Holdings, Inc. Announces CFO Changes	23-05-17	CI
Coeptis Therapeutics Names Brian Cogley as Finance Chief	23-05-17	MT
Coeptis Therapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
JonesTrading Initiates Coeptis Therapeutics at Buy With $4 Price Target	23-04-19	MT
Coeptis Therapeutics Gets Exclusive Right to Negotiate Deal With Deverra Therapeutics	23-04-18	MT

Chart Coeptis Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc. and Coeptis Pharmaceuticals, LLC., is a biopharmaceutical company. The Company owns, acquires, and develops cell therapy technologies for cancer and other diseases. Its product portfolio and rights are highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen chimeric antigen receptor (CAR) T technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms, which the Company is developing with VyGen-Bio and medical researchers at the Karolinska Institute. Its CAR therapy is a treatment for cancer in which a patient's T cells are genetically engineered to recognize cancer cells to target and destroy them.

Sector

Pharmaceuticals

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+27.00%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+13.09%	231B
NOVARTIS AG	+5.46%	200B
ROCHE HOLDING AG	-9.61%	195B
AMGEN INC.	-6.26%	145B

Other Pharmaceuticals